NewsFeed Voices Science Insight Innovation
January, 2026
January 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Wolfgang Miesbach Explains The New 2-year Survival Data from the GTH-AHA-EMI Study
Wolfgang Miesbach/LinkedIn
Nov 24, 2025, 14:31

Wolfgang Miesbach Explains The New 2-year Survival Data from the GTH-AHA-EMI Study

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:

”This slide you’ll be seeing more often!

In acquired haemophilia A, this Kaplan-Meier survival curve demonstrates a remarkable 19% absolute survival benefit: The 2-year survival data from the GTH-AHA-EMI study just published shows something remarkable: 82% versus 63%, when emicizumab prophalxis lead to postponed immunosuppression (GTH-AHA-EMI) versus 63% with immediate IST (GTH-AH 01/2010).

The paradigm change: Emicizumab prophylaxis combined with postponed immunosuppression (IST) can protect patients from bleeding while deferring the intensive IST until they’re better able to tolerate it, what is fundamentally shifting the risk-benefit equation.

What else is new?

  • Fatal infections: 4% with the new strategy vs. 16% with immediate IST – a 75% reduction in infection-related mortality
  • Mortality reduction: The hazard ratio was slashed by 61% (HR 0.39)
  • Efficacy maintained: 76% of patients achieved complete remission
  • New IST regimens: 56% of patients received rituximab (vs. only 20% in the historical cohort), with lower cumulative corticosteroid doses and less cyclophosphamide exposure
  • Spontaneous remission opportunity: 6 patients (15%) achieved remission without IST – a rate we couldn’t observe when forced into immediate treatment
  • Safer IST introduction: When bleeding is controlled and patients are ambulatory, IST becomes nonurgent and can be introduced at lower risk of nosocomial infections

As the accompanying excellent commentary by Teitel and St-Louis emphasizes: effective prophylaxis renders IST nonurgent.

This isn’t a rigid protocol – it’s clinical flexibility that allows individualized decision-making for our frail AHA patients.

The full paper is now live in Blood Advances.

Congratulations to Andreas Tiede and the GTH-AHA working group on this outstanding study!”

Read the full article here.

Article: Sustained survival benefit of emicizumab and postponed immunosuppression in acquired hemophilia A

Authors: Inga M. Schimansky, Christiane Dobbelstein, Robert Klamroth, Christina Hart, Ulrich J. Sachs, Richard Greil, Paul Knöbl, Johannes Oldenburg, Wolfgang Miesbach, Christian Pfrepper, Karolin Trautmann-Grill, Patrick Möhnle, Katharina Holstein, Hermann Eichler, Sonja Werwitzke, Andreas Tiede

Wolfgang Miesbach Explains The New 2-year Survival Data from the GTH-AHA-EMI Study

Stay updated with Hemostasis Today.

Andreas Tiede bleeding disorders Christian Pfrepper Christiane Dobbelstein Christina Hart Emicizumab GTH-AHA haemophilia A Health Hematology Hemostasis Hemostasis Today Hermann Eichler Immunosuppression Inga M. Schimansky IST Johannes Oldenburg Karolin Trautmann-Grill Katharina Holstein Medicine Patrick Möhnle Paul Knöbl Richard Greil Robert Klamroth Sonja Werwitzke Ulrich J. Sachs Wolfgang Miesbach
NewsFeed